Validity of biomarkers in screening for neonatal sepsis – A single center –hospital based study

Rashwan, Nagwan I.; Hassan, Mohammed H.; El-Deen, Zeinab M Mohey; Ahmed, Ahmed El-Abd

doi:10.1016/j.pedneo.2018.05.001

Cited by 45 publications

(54 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical signs and symptoms are not specific, as well. Sepsis overestimation and overtreatment are also reported as the other challenging complications that should be extremely avoided [17,[19][20][21]. Recent investigations have introduced different sepsis diagnostic biomarkers to determine their utility for early detection of NEOS, leading better neonatal outcomes; IL-6, presepsin, serum interleukin-33, Interleukin-27, salivary C-reactive protein, mean platelet volume, and neutrophil/lymphocyte ratio are some of them [21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Assessment of serum interleukin-35 as a diagnostic biomarker of neonatal early-onset sepsis

et al. 2019

View full text Add to dashboard Cite

Neonatal sepsis is a life-threatening disorder among infants, which is associated with high morbidity and mortality. In recent years, although the management of newborns has improved, early diagnosis and treatment of neonatal earlyonset sepsis (NEOS) are the major challenges for neonatologists in Neonatal intensive care units (NICUs). We assessed the diagnostic value of interleukins-35 (IL-35) in diagnosis of NEOS. A prospective process evaluation study was carried out in the NICU of Akbar-Abadi and Ali-Asghar Hospitals affiliated to Iran University of Medical Sciences from 2017 to 2018. Eighty hospitalized neonates with clinical suspicion of sepsis in the first 72 h of life entered the study by convenience or accidental sampling. Routine hematology tests regarding sepsis diagnosis were performed after admission. All subjects were assigned into two groups: newborns with proven sepsis and newborns with suspected sepsis. IL-35 levels in septic and unlikely infected hospitalized newborns were measured using Elisa Kit (ZellBio GmbH. Cat. No; ZB-10042C-H9648, Human Interleukin 35), and the results were compared. The mean IL-35 in serum samples from septic neonates was significantly higher than this variable in samples from unlikely infected newborns (13.41 ± 2.4 vs. 9.02 ± 2.6 pg/ml; p < 0.0001). The area under receiver-operating characteristic (ROC) curve for IL-35 was 0.895 (CI 95% = 0.826-0.963; p = 0.0001). The result of study showed serum IL-35 had a moderate accuracy (AUC = 0.895) for the diagnosis of NS. Therefore, serum IL-35 could be suggested as a predictive biomarker in neonatal early-onset sepsis. Further studies with larger sample size are strongly suggested.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of serum interleukin-35 as a diagnostic biomarker of neonatal early-onset sepsis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This study did have some limitations in that the study group was fairly small (51 neonates) and there was no defined control group. Other studies have demonstrated a significant difference in PCT concentrations between neonates with sepsis and healthy controls [56], and that PCT is higher in proven as opposed to probable sepsis; it is also higher in non-survivors than survivors, hinting at possible prognostic use [57]. Very encouraging diagnostic performance was found by Hahn and co-workers, who calculated an AUC of 0.87 for PCT in differentiating between controls and cases of proven sepsis [58].…”

Section: Neonatesmentioning

confidence: 93%

“…They further suggested that combining IL-6 and CRP increased the sensitivity and specificity when compared to the use of either biomarker individually. This combination was also advocated by Rashwan and co-workers [57], who concluded that the use of individual biomarkers is not suitable for sepsis diagnosis. Despite this, they concluded that IL-6 has similar diagnostic power to presepsin, although both were outperformed by CRP.…”

Section: Neonatesmentioning

confidence: 99%

“…The authors also combined presepsin and PCT and actually found that this decreased the diagnostic power, producing an AUC of 0.263; this finding was not commented upon. Despite this, the combination of presepsin with other biomarkers such as CRP, PCT or IL-6 has been said to increase overall diagnostic power [57]. One study based on a cohort of preterm neonates born before 34 weeks gestation [83] measured presepsin at enrolment, and after three and seven days.…”

Section: Neonatesmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for Point-of-Care Diagnosis of Sepsis

2020

View full text Add to dashboard Cite

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In 2017, almost 50 million cases of sepsis were recorded worldwide and 11 million sepsis-related deaths were reported. Therefore, sepsis is the focus of intense research to better understand the complexities of sepsis response, particularly the twin underlying concepts of an initial hyper-immune response and a counter-immunological state of immunosuppression triggered by an invading pathogen. Diagnosis of sepsis remains a significant challenge. Prompt diagnosis is essential so that treatment can be instigated as early as possible to ensure the best outcome, as delay in treatment is associated with higher mortality. In order to address this diagnostic problem, use of a panel of biomarkers has been proposed as, due to the complexity of the sepsis response, no single marker is sufficient. This review provides background on the current understanding of sepsis in terms of its epidemiology, the evolution of the definition of sepsis, pathobiology and diagnosis and management. Candidate biomarkers of interest and how current and developing point-of-care testing approaches could be used to measure such biomarkers is discussed.

show abstract

“…Neonatal sepsis is an in ammatory system syndrome caused by bacteria or viruses, which is the main cause of neonatal morbidity and death [1][2][3].Researchers have been looking for an ideal biomarker with high sensitivity and speci city in order to diagnose and eliminate neonatal sepsis as early as possible [4].Currently, the most commonly used biomarkers are C-reactive protein(CRP),micro-erythrocyte sedimentation rate and procalcitonin (PCT) and serum amyloid A [5][6][7].However, the speci city of these indicators is poor, and their clinical application is limited.So far, no ideal biomarker can meet the standard [8,9].Therefore, exploring new diagnostic methods and molecular mechanisms is essential for neonatal sepsis.…”

Section: Introductionmentioning

confidence: 99%

MIR-141 is Negatively Correlated With TLR4 in Neonatal Sepsis and Regulates LPS-induced Inflammatory Responses in Monocytes

Lin

Wang

2020

Preprint

View full text Add to dashboard Cite

Background: Neonatal sepsis is an inflammatory system syndrome caused by bacteria or viruses, which is the main cause of neonatal morbidity and mortality. But currently there is a lack of an ideal biomarker to meet the standard. The abnormally expression of miRNAs may be a group of potential diagnostic biomarkers in neonatal sepsis.Methods: First, qRT-PCR was used to calculate the expression of miR-141 in the serum of neonatal with sepsis and control. The diagnostic value of PCT and serum miR-141 was evaluated by receiver operating characteristic (ROC) curve. Second, the relationship between miR-141 and TLR4 was verified using luciferase report assay. An inflammation model was established using monocytes with the LPS treatment. Elisa analyzed the relationship between miR-141 and inflammatory factors.Results: qRT-PCR found that the expression of miR-141 in neonatal sepsis was significantly lower than healthy controls. ROC curve shows that miR-141 has high diagnostic accuracy. LPS stimulation in monocytes also led to a decrease in the expression of miR-141. Luciferase report assay proves that miR-141 can target and regulate TLR4 expression. ELISA proved that overexpression of miR-141 has the effect of inhibiting the LPS-induced inflammation in monocytes.Conclusion: In conclusion, miR-141 serves as a candidate diagnostic biomarker and is involved in the regulation of inflammatory response in the development of neonatal sepsis. Overexpression of miR-141 inhibits LPS-induced inflammation by targeting TLR4. Therefore, miR-141 is expected to be a potential diagnostic biomarker and a therapeutic target in neonatal sepsis.

show abstract

Validity of biomarkers in screening for neonatal sepsis – A single center –hospital based study

Cited by 45 publications

References 31 publications

Assessment of serum interleukin-35 as a diagnostic biomarker of neonatal early-onset sepsis

Assessment of serum interleukin-35 as a diagnostic biomarker of neonatal early-onset sepsis

Biomarkers for Point-of-Care Diagnosis of Sepsis

MIR-141 is Negatively Correlated With TLR4 in Neonatal Sepsis and Regulates LPS-induced Inflammatory Responses in Monocytes

Contact Info

Product

Resources

About